Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11453589rdf:typepubmed:Citationlld:pubmed
pubmed-article:11453589lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C0305065lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C0683325lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:11453589lifeskim:mentionsumls-concept:C0016674lld:lifeskim
pubmed-article:11453589pubmed:issue5lld:pubmed
pubmed-article:11453589pubmed:dateCreated2001-7-16lld:pubmed
pubmed-article:11453589pubmed:abstractTextA surveillance program for invasive pneumococcal disease was undertaken in Puyde-D?me, an administrative district of the region Auvergne in France, from 1 January 1994 to 31 December 1998. A total of 214 cases were identified. The annual incidence of invasive pneumococcal disease increased (P=0.04) from 5.5 in 1994 to 9.3 cases per 10(5) person-years in 1998. The highest incidences were for children <2 years of age (59.2 cases per 10(5) person-years) and for adults > or = 65 years (18 cases per 10(5) person-years). Clinical diagnoses, available in 200 patients, included acute pneumonia (62%), meningitis (10%), sepsis without focus (20%), and others (8%). The most frequent chronic medical conditions of the patients included smoking, alcoholism, cardiovascular and pulmonary diseases, and malignancies. Thirty-one percent of the isolates were nonsusceptible to penicillin. Penicillin resistance (MIC > or = 0.1 mg/l) was more frequent (P=0.02) in cancer patients. The overall case-fatality rate was 21.5%. Risk factors for death were age, sex, and underlying diseases of the patients, along with the severity of illness. These population-based findings should convince clinicians to offer pneumococcal vaccine to patients at high risk for invasive pneumococcal disease, thereby increasing vaccination coverage levels in France.lld:pubmed
pubmed-article:11453589pubmed:languageenglld:pubmed
pubmed-article:11453589pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11453589pubmed:citationSubsetIMlld:pubmed
pubmed-article:11453589pubmed:statusMEDLINElld:pubmed
pubmed-article:11453589pubmed:monthMaylld:pubmed
pubmed-article:11453589pubmed:issn0934-9723lld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:AndréMMlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:PoirierVVlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:SouweineBBlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:CaillaudDDlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:NguyenL TLTlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:LabbéAAlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:De ChampsCClld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:LaurichesseHHlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:RuivardMMlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:BeytoutJJlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:RomaszkoJ PJPlld:pubmed
pubmed-article:11453589pubmed:authorpubmed-author:GuólonDDlld:pubmed
pubmed-article:11453589pubmed:issnTypePrintlld:pubmed
pubmed-article:11453589pubmed:volume20lld:pubmed
pubmed-article:11453589pubmed:ownerNLMlld:pubmed
pubmed-article:11453589pubmed:authorsCompleteYlld:pubmed
pubmed-article:11453589pubmed:pagination299-308lld:pubmed
pubmed-article:11453589pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:meshHeadingpubmed-meshheading:11453589...lld:pubmed
pubmed-article:11453589pubmed:year2001lld:pubmed
pubmed-article:11453589pubmed:articleTitleClinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dôme, France, 1994-1998.lld:pubmed
pubmed-article:11453589pubmed:affiliationInfectious Diseases Department, Hôtel-Dieu, University Hospital of Clermont-Ferrand, France. hlaurichesse@chu-clermontferrand.frlld:pubmed
pubmed-article:11453589pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11453589lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11453589lld:pubmed